Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database Analysis

Prostate Cancer and Prostatic Diseases, Published online: 28 November 2019; doi:10.1038/s41391-019-0191-9Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database Analysis
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Source Type: research

Related Links:

Interview with Trevor J. Royce, MD MS MPH, author of Analysis of Price Transparency via National Cancer Institute–Designated Cancer Centers’ Chargemasters for Prostate Cancer Radiation Therapy
Source: JAMA Specialty Journals Author Interviews - Category: General Medicine Authors: Source Type: podcasts
This cohort study compares functional outcomes, including sexual and bowel function and urinary incontinence, associated with active surveillance, surgery, or radiation therapy 5 years after treatment.
Source: JAMA - Category: General Medicine Source Type: research
Abstract BACKGROUND: Novel methods of risk stratification are needed for men with prostate cancer. The Prostate Imaging Reporting and Data System (PI-RADS) uses multiparametric MRI (mpMRI) to assign a score indicating the likelihood of clinically significant prostate cancer. We evaluated pretreatment mpMRI findings, including PI-RADS score, as a marker for outcome in patients treated with primary radiation therapy (RT). METHODS: One hundred and twenty-three men, 64% and 36% of whom had National Comprehensive Cancer Network (NCCN) intermediate-risk and high-risk disease, respectively, underwent mpMRI prior to ...
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
Authors: Antonelli A, Palumbo C, Noale M, Artibani W, Bassi P, Bertoni F, Bracarda S, Bruni A, Corvò R, Gacci M, Magrini SM, Montironi R, Porreca A, Tubaro A, Zagonel V, Maggi S, and the Pros-IT CNR study group Abstract BACKGROUND: We assessed patients and tumor characteristics, as well as health-related quality of life (HRQoL) items, associated with curative intent treatment decision-making in clinically localized prostate cancer (PCa) patients. METHODS: Clinically localized PCa treated with either radical prostatectomy (RP) or radiation therapy (RT) within 12 months from diagnosis were abstracted from ...
Source: Minerva Urologica e Nefrologica - Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research
ConclusionsMost patients declined the convenience of moderate hypofractionation due to potentially increased acute toxicity, and the uncertainty of long-term outcomes. We advocate that no patient should be offered hypofractionation without a thorough discussion of uncertainty and acute toxicity.
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Advances in positron emission tomography (PET) imaging with prostate-specific tracers allow more sensitive and specific detection of low-volume recurrences that were previously indiscernible using conventional imaging. Retrospective data in patients presenting with N1M0 prostate cancer support combined-modality therapy with radiation and androgen deprivation therapy, and preliminary data from the Radiation Therapy Oncology Group 0534 randomized trial suggest that salvage pelvic nodal radiation therapy with androgen deprivation therapy is safe and effective for patients with biochemical recurrence after prostatectomy.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
A 60-year-old male has a medical history of prostate adenocarcinoma. He was treated in 2013 for an unfavorable intermediate-risk prostate cancer (Gleason score 4  + 3 = 7, prostate-specific antigen [PSA] 9.1, and T1c). Because of his unfavorable risk features, he underwent combined-modality treatment with external beam radiation therapy and prostate seed implantation. His PSA dropped to 0.20 (October 2015). His PSA trend is as follows: 0.88 (April 2016), 1.5 (March 2017), and 4.4 (January 2018). Multiparametric magnetic resonance imaging of the pelvis showed scattered multiple lymph nodes, measuring up ...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
Background: Mucinous prostate cancer (PCa) is an extremely rare form of prostate malignancy. To date, the limited knowledge of its biology and outcomes stems from mostly small, single institution experiences. We analyzed the Surveillance, Epidemiology, and End Results (SEER) database to explore the incidence and treatment of mucinous PCa together with its prognostic factors to gain relatively large and consolidated insights.Methods: Age-adjusted incidence (AAI) rates were evaluated over time. Propensity score matching (PSM) and Kaplan–Meier analyses were used to compare the prognosis between mucinous PCa and typical ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
A 75-year-old man, treated with curative intent for histopathologically proven prostate cancer (initial prostate-specific antigen, 27 ng/mL; Gleason 4 + 5 = 9) through external beam radiation therapy in 2010 in combination with 3 years of androgen deprivation therapy (leuprorelin), underwent 18F-DCFPyL PET/CT for biochemical recurrence with a prostate-specific antigen of 4.1 ng/mL in February 2019. Multiple pelvic and some para-aortic lymph nodes showed highly increased 18F-DCFPyL uptake, suspicious for metastases. Incidentally, a solid mesenteric mass and mesenteric lymph nodes with moderately increased 18F-DCFPyL uptake ...
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
Abstract AIM: To report toxicity and quality of life (QOL) outcomes from a randomised trial of prostate only versus whole pelvic radiotherapy in high risk, node negative prostate cancer. MATERIALS/METHODS: Patients with localised prostate adenocarcinoma and nodal involvement risk > 20%, were randomised to prostate only (PORT, 68 Gy/25# to prostate) and whole pelvis (WPRT, 68 Gy/25# to prostate and 50 Gy/25# to pelvis) arms with stratification for TURP, Gleason score, baseline PSA, and type of androgen deprivation therapy (ADT). Image guided intensity modulated radiotherapy (IG-IMRT...
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Prostate Cancer | Radiation Therapy | Urology & Nephrology